TET2 and prostate adenocarcinoma: TET2 expression was measured in patients with various types of cancers, and it was upregulated in low-grade glioma patients (63) but downregulated in ccRCC (110, 111), ovarian cancer (112) and prostate adenocarcinoma (113) patients.